Last ¥1,145 JPY
Change Today -23.00 / -1.97%
Volume 2.6M
4151 On Other Exchanges
Symbol
Exchange
Munich
Tokyo
OTC US
As of 1:00 AM 12/19/14 All times are local (Market data is delayed by at least 15 minutes).

kyowa hakko kirin co ltd (4151) Snapshot

Open
¥1,173
Previous Close
¥1,168
Day High
¥1,175
Day Low
¥1,140
52 Week High
07/31/14 - ¥1,510
52 Week Low
03/20/14 - ¥1,006
Market Cap
660.1B
Average Volume 10 Days
2.0M
EPS TTM
¥34.33
Shares Outstanding
576.5M
EX-Date
12/26/14
P/E TM
33.4x
Dividend
¥25.00
Dividend Yield
2.18%
Current Stock Chart for KYOWA HAKKO KIRIN CO LTD (4151)

Related News

No related news articles were found.

kyowa hakko kirin co ltd (4151) Related Businessweek News

No Related Businessweek News Found

kyowa hakko kirin co ltd (4151) Details

Kyowa Hakko Kirin Co., Ltd. manufactures and markets pharmaceuticals and bio-chemicals primarily in Asia, Europe, and the United States. The company’s Pharmaceuticals segment researches, develops, produces, and sells ethical drugs for the treatment of various diseases, including renal anemia, oncology, allergies, and hypertension. Its principal ethical drugs include NESP/ESPO, an ESA formulation; REGPARA, a secondary hyperparathyroidism; CONIEL, a hypertension and angina pectoris; ONGLYZA, a treatment for type 2 diabetes; GRAN, a G-CSF agent; Fentos, a transdermal product; POTELIGEO, an adult T-cell leukemia-lymphoma; Romiplate, a chronic idiopathic thrombocytopenic purpur; ALLELOCK, an antiallergic agent; Patanol antiallergic eye drops; ASACOL, an ulcerative colitis treatment; NOURIAST, an antiparkinsonian agent; and DEPAKENE, an antiepileptic agent. This segment also offers in vitro diagnostic reagents, such as POTELIGEO tests and Determiner clinical chemistry diagnostic reagents. The company’s Bio-chemicals segment produces and sells amino acids, nucleotides, and related compounds for use in pharmaceuticals and their intermediates, health foods, dietary supplements, and cosmetics. This segment also produces plant growth regulators; designs and installs plant facilities and equipment; manufactures active pharmaceutical ingredients, pharmaceutical intermediates, industrial raw materials, and health care products; sale of fine chemicals; and is involved in mail-order sale of healthcare products in Japan. In addition, the company is engaged in pharmaceuticals licensing, as well as insurance, wholesale, and retail activities. The company was founded in 1949 and is headquartered in Tokyo, Japan. Kyowa Hakko Kirin Co., Ltd. is a subsidiary of Kirin Holdings Company, Limited.

7,152 Employees
Last Reported Date: 03/14/14
Founded in 1949

kyowa hakko kirin co ltd (4151) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

kyowa hakko kirin co ltd (4151) Key Developments

Ono Pharmaceutical, Bristol-Myers Squibb and Kyowa Hakko Kirin Announces Immuno-Oncology Clinical Collaboration Studying Opdivo (nivolumab) and Mogamulizumab in Advanced Solid Tumors

Ono Pharmaceutical Co.,Ltd. Bristol-Myers Squibb Company and Kyowa Hakko Kirin Co., Ltd. announced the companies have entered into a clinical trial collaboration agreement to conduct a Phase 1 combination study with Opdivo (nivolumab), a PD-1 immune checkpoint inhibitor, and mogamulizumab, an anti-CCR4 antibody. The study, which will be conducted in Japan, will focus on evaluating the safety, tolerability and anti-tumor activity of combining Opdivo and mogamulizumab as a potential treatment option for patients with advanced or metastatic solid tumors. Opdivo, launched in Japan in September 2014 for the treatment of patients with unresectable melanoma, is being developed in multiple tumor types in more than 50 clinical trials worldwide. Mogamulizumab was launched in Japan in May 2012 for the treatment of relapsed or refractory CCR4-positive Adult T-cell Leukemia-Lymphoma (ATL), and granted the indication expansion in March 2014 for relapsed or refractory CCR4-positive Peripheral T-Cell Lymphoma (PTCL) and Cutaneous T-Cell Lymphoma (CTCL). Clinical trials with mogamulizumab in ATL, PTCL, and CTCL are ongoing in the U.S., European Union (EU) and other countries. Opdivo and mogamulizumab are part of a new class of cancer treatments known as immunotherapies, which are designed to harness the body's own immune system in fighting cancer by targeting distinct regulatory components of the immune system. Opdivo binds to the checkpoint receptor PD-1 expressed on activated T-cells, blocking this pathway and enabling the immune system to attack tumors, while mogamulizumab can suppress some of the immune cells that shield the tumor from the immune system. Pre-clinical evidence for each therapy suggests the combination of Opdivo and mogamulizumab may lead to an enhanced anti-tumor immune response compared to either agent alone.

Kyowa Hakko Kirin Co., Ltd. Announces Launch of Sustained-Duration G-CSF Product G-Lasta ® in Japan

Kyowa Hakko Kirin Co., Ltd. announced that sustained-duration G-CSF product G-Lasta ® subcutaneous injection 3.6mg (G-Lasta ®) [generic name: pegfilgrastim (genetical recombination)] will be launched in Japan on November 28, 2014. G-Lasta ® is a sustained duration form of Granulocyte Colony-Stimulating Factor (G-CSF) product, which is produced by PEGylation of filgrastim, for decreasing the incidence of chemotherapy-associated febrile neutropenia. While filgrastim requires repeated daily doses over several days, G-Lasta ® shows comparable efficacy with a single dose per chemotherapy cycle. G-Lasta ® is therefore expected to reduce the burden of drug administration and to decrease frequent hospital visits of outpatients undergoing chemotherapy. Also, prophylactic administration of G-Lasta ® prior to febrile neutropenia is expected to reduce risks of infection, which results in clinical benefits such as improving the compliance with doses and schedules of chemotherapy. Pegfilgrastim, originally generated by Amgen Inc., was licensed from Kirin-Amgen Inc., to Kyowa Hakko Kirin. It has already been approved in 107 countries and regions around the world. G-CSF is a protein produced by using gene recombination. G-CSF selectively stimulates production of neutrophils and also enhances the neutrophil function. Based on this mechanism, G-CSF is used to accelerate recovery from chemotherapy-induced neutropenia, and it reduces various risks associated with neutropenia.

Kyowa Hakko Kirin Announces Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014; Revised Earnings Guidance for the Full Year Ending December 31, 2014; Provides Dividend Guidance for the Full Year Ending December 31, 2014

Kyowa Hakko Kirin announced consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter, the company posted a 50% drop in net income compared to a year earlier, following a decline in licensing revenue and the impact of a drug price revision. The company posted net income of JPY 2.8 billion, compared to JPY 5.6 billion in the same period a year earlier. Net sales were JPY 77 billion, versus JPY 82.3 billion in the year-ago period. For the nine months, the company posted JPY 238,936 million, down 5.2% from the year-ago period, and net income of JPY 12,036 million against JPY 23,323 million, down 48.4%, with domestic sales of ethical pharmaceutical treatments falling following a drug price revision in April. Operating income was JPY 26,277 million against JPY 41,409 million, a year ago. Ordinary income was JPY 23,800 million against JPY 39,203 million, a year ago. Fully diluted net income per share was JPY 21.97 against JPY 42.58, a year ago. Income before income taxes and minority interests was JPY 22,586 million against JPY 40,498 million, a year ago. The company revised down its full-year earnings forecasts, targeting net income of JPY 18 billion and net sales of JPY 336 billion, compared to earlier forecasts of JPY 20 billion and JPY 337 billion, respectively. For the full year ending December 31, 2014, the company also expects net income per share of JPY 32.89 per share, operating income of JPY 43,000 million and ordinary income of JPY 35,000 million. The company provided dividend guidance for the full year ending December 31, 2014. For the period, the company expects year-end dividend per share of JPY 12.50 against JPY 12.50, a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
4151:JP ¥1,145.00 JPY -23.00

4151 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Albemarle Corp $58.69 USD -0.15
Genmab A/S kr352.70 DKK -1.40
MorphoSys AG €77.05 EUR -9.44
Nabaltec AG €12.04 EUR +0.034
Seattle Genetics Inc $32.89 USD -0.15
View Industry Companies
 

Industry Analysis

4151

Industry Average

Valuation 4151 Industry Range
Price/Earnings 30.6x
Price/Sales 1.8x
Price/Book 1.0x
Price/Cash Flow 15.7x
TEV/Sales 1.7x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact KYOWA HAKKO KIRIN CO LTD, please visit www.kyowa-kirin.co.jp. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.